Aktis Oncology filed to go public in the U.S., aiming to raise roughly $181.7 million at a $16–$18 per‑share range with an option that could lift proceeds to about $209.6 million. The company plans to use most proceeds to advance its lead miniprotein radiopharmaceutical Ac‑AKY‑1189 in Phase 1b for Nectin‑4 tumors and to initiate a Phase 1b for Ac‑AKY‑2519 targeting B7‑H3. Aktis has drawn Big Pharma backers in prior rounds and argues its imaging‑guided patient selection for radiopharmaceuticals could broaden indications beyond current ADC competitors.